Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2019

Oct 28, 2019

30718_dirs_2019-10-28_daa61ced-7b83-4ff4-b374-a4418fe8c16a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2019-10-24

Reporting Person: Nusse Roeland (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-10-24 Common Stock A 495 Acquired 5721 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-10-24 Stock Option (right to buy) $201.64 A 2011 Acquired 2029-10-24 Common Stock (2011) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $60.46 2020-05-25 Common Stock (10000) 10000 Direct
Stock Option (right to buy) $61.46 2020-10-27 Common Stock (5000) 5000 Direct
Stock Option (right to buy) $70.35 2021-10-26 Common Stock (5000) 5000 Direct
Stock Option (right to buy) $66.90 2022-10-24 Common Stock (5000) 5000 Direct
Stock Option (right to buy) $87.39 2023-10-30 Common Stock (4000) 4000 Direct
Stock Option (right to buy) $91.78 2024-10-30 Common Stock (4000) 4000 Direct
Stock Option (right to buy) $87.34 2025-10-28 Common Stock (4260) 4260 Direct
Stock Option (right to buy) $101.19 2026-10-27 Common Stock (3985) 3985 Direct
Stock Option (right to buy) $125.05 2027-10-26 Common Stock (3125) 3125 Direct
Stock Option (right to buy) $179.84 2028-10-25 Common Stock (1898) 1898 Direct

Footnotes

F1: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders.